Gastroenteritis

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Retrieved on: 
Thursday, March 28, 2024

Our drug-discovery process focuses on the highly conserved regions of the viral enzymes and inhibitor-enzyme interactions at the atomic level.

Key Points: 
  • Our drug-discovery process focuses on the highly conserved regions of the viral enzymes and inhibitor-enzyme interactions at the atomic level.
  • Cocrystal reported unrestricted cash as of December 31, 2023 of $26.4 million, compared with $37.1 million as of December 31, 2022.
  • Net cash used in operating activities for 2023 was $14.7 million, compared with $21.4 million for 2022.
  • The Company had working capital of $25.0 million and 10.2 million common shares outstanding as of December 31, 2023.

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, March 20, 2024

BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis.

Key Points: 
  • “Over the past year, we made significant progress with HIL-214, our vaccine candidate for the prevention of moderate-to-severe norovirus related acute gastroenteritis.
  • As of October 2023, HilleVax has completed enrollment of subjects in all three clinical trials.
  • As of December 31, 2023 and December 31, 2022, the company had cash, cash equivalents and marketable securities totaling $303.5 million and $279.4 million, respectively.
  • Other income for the fourth quarter 2023 was $3.3 million, compared to $1.9 million for the fourth quarter 2022.

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.

Retrieved on: 
Monday, March 18, 2024

“MLD is a rapidly progressing, life-limiting and ultimately fatal rare disease that has a devastating impact on afflicted children and their families.

Key Points: 
  • “MLD is a rapidly progressing, life-limiting and ultimately fatal rare disease that has a devastating impact on afflicted children and their families.
  • This achievement is the culmination of decades of research and development in partnership with our academic and clinical collaborators at the San Raffaele-Telethon Institute for Gene Therapy.
  • It was previously given both Rare Pediatric Disease (RPD) and Regenerative Medicine Advanced Therapy (RMAT) designations from FDA.
  • Orchard Therapeutics will provide more details about the launch of Lenmeldy in the U.S. through a separate announcement this week.

How worried should I be about cryptosporidiosis? Am I safe at the pool?

Retrieved on: 
Thursday, February 15, 2024

More than 700 cases of this gastrointestinal disease were reported in Queensland in January, which is 13 times more than in January last year.

Key Points: 
  • More than 700 cases of this gastrointestinal disease were reported in Queensland in January, which is 13 times more than in January last year.
  • Read more:
    What lies beneath: the bugs lurking in your swimming pool

What causes cryptosporidiosis, and who is affected?

  • Cryptosporidum hominis only affects humans and is the major cause of recent outbreaks in Australia, while Cryptosporidium parvum can also affect animals.
  • The infection is spread by spores called oocysts in the stools of humans and animals.
  • Cryptosporidiosis is more prevalent in young children, particularly those under five, but the disease can affect people of any age.

So how do we catch it?

  • The largest recorded outbreak occurred in Milwaukee in 1993 where 403,000 people were believed to have been infected.
  • As few as ten oocysts can cause infection, making it possible for contaminated drinking water to affect a very large number of people.
  • Oocysts have been found in foods such as fresh vegetables and seafood but these are not common sources of infection in Australia.

What about chlorine?

  • Young children and in particular children in nappies are known to increase the potential for disease transmission in recreational water.
  • Proper nappy changing, frequent bathroom breaks and showering before swimming to remove faecal residue are helpful ways to reduce the risk.

Some sensible precautions


Other measures you can take to reduce yours and others’ risk of cryptosporidiosis include:
avoid swimming in natural waters such as rivers and creeks during and for at least three days after heavy rain
avoid swimming in beaches for at least one day after heavy rain
avoid drinking untreated water such as water from rivers or springs. If you need to drink untreated water, boiling it first will kill the Cryptosporidium
avoid swallowing water when swimming if you can
if you’ve had diarrhoea, avoid swimming for at least two weeks after it has resolved
avoid sharing towels or linen for at least two weeks after diarrhoea has resolved
avoid sharing, touching or preparing food that other people may eat for at least 48 hours after diarrhoea has resolved
wash your hands with soap and water after going to the bathroom or before preparing food (Cryptosporidium is not killed by alcohol gels and sanitisers).
Not all cases of diarrhoea are due to cryptosporidiosis. There are many other causes of infectious gastroenteritis and because the vast majority of the time recovery is uneventful you don’t need to see a doctor unless very unwell. If you do suspect you may have cryptosporidiosis you can ask your doctor to refer you for a stool test.
Vincent Ho does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

Retrieved on: 
Wednesday, February 14, 2024

The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).

Key Points: 
  • The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).
  • Remarkably, the trial is progressing ahead of schedule and with the addition of RMOC is now projected to conclude enrollment by Q1/2024.
  • I’m excited about the potential opportunity STAR-LLD can bring to multiple myeloma patients.”
    Earlier last month, Starton disclosed preliminary trial findings regarding the safety and efficacy of STAR-LLD for multiple myeloma.
  • Notably, no hematologic toxicities greater than Grade 1 have been observed following up to 3 cycles of treatment thus far.

Nigeria’s street food: tasty but toxic? Expert shares advice to make it safer

Retrieved on: 
Thursday, February 8, 2024

From the sizzling suya snack in Abuja to the aromatic jollof rice in Lagos, street food has become an integral part of Nigerian life.

Key Points: 
  • From the sizzling suya snack in Abuja to the aromatic jollof rice in Lagos, street food has become an integral part of Nigerian life.
  • However, beneath these enticing flavours lies a critical question of public safety and health regulation.
  • Other studies have focused on the microbiological safety of street foods (for example, soy wara, a Nigerian curdled soy milk product), and the risk factors in street food practices.
  • While street food vendors provide affordable and accessible meals, the lack of regulation poses significant health risks.

Why street food can be unsafe

  • Inadequate access to clean water, inappropriate waste disposal, temperature abuse and lack of food safety knowledge are common challenges seen among street food vendors.
  • Generally, street food preparation in Nigeria mirrors traditional approaches to food preparation at home.
  • Similarly, many street food vendors operate in less than perfect environments for food processing: many street food vendor stands have flies, rodents and open waste bins which are risk factors for the contamination of foods.

Checking unsafe practices


A multifaceted approach to these issues must be adopted.
Training: First, basic food safety training for vendors is crucial. This training should cover essential hygiene practices, safe food handling and storage procedures. It can be done through local health departments and community organisations. This recommendation draws on established principles of hygiene and safe food handling. Continuous training on food safety has proved effective in promoting food safety.

  • This requires a balance between ensuring public health and not stifling the livelihoods of the vendors.
  • Supplying vendors with hygienic materials has proved to be valuable for preserving and enhancing food safety in low- and middle-income nations.


Inspection: Regular inspections should be conducted to ensure compliance with these regulations. These should not be punitive but rather supportive, helping vendors to meet the required standards. A food hygiene rating scheme should be put in place to identify vendors complying with food safety standards as this could motivate them to improve their sanitary conditions.
Awareness: Public awareness also plays a vital role. Consumers should be educated about the importance of food safety and how to identify vendors who adhere to hygiene standards. Consumer awareness can create a demand for safer practices, encouraging vendors to comply with regulations.
Research and development: Finally, research and collaboration with food scientists and public health experts can lead to innovative solutions that are tailored to the Nigerian context. For instance, exploring low-cost preservation techniques or developing mobile apps for health inspection ratings could revolutionise the way street food is regulated.

Regulations will save lives and livelihoods


Regulating street food in Nigeria is not just about preventing disease; it is about preserving a way of life in a safe and sustainable manner. At the heart of this issue are the vendors and consumers, whose lives and well-being are interconnected with the very essence of street food culture.
Helen Onyeaka does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

PhageLab Raises $11 Million to Develop Bacteriophage Solutions to Treat Bacterial Outbreaks in the Livestock Industry

Retrieved on: 
Tuesday, January 23, 2024

PhageLab will also use the funding to expand its global team, which currently has close to 100 employees across Latin America and Europe.

Key Points: 
  • PhageLab will also use the funding to expand its global team, which currently has close to 100 employees across Latin America and Europe.
  • Antibiotic-resistant outbreaks in livestock farming have been increasing, due to the high emergence rate of multidrug treatment-resistant bacteria.
  • The platform employs AI to generate “customized cocktails,” that can effectively manage pathogenic bacteria in the livestock industry and reduce antibiotic dependence.
  • PhageLab uses this library to create custom solutions in 45 days, that is safe and effective for use to eliminate livestock bacteria.

Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Wednesday, January 3, 2024

Remarkably, there were no hematologic toxicities greater than Grade 1 observed to date. Only a single drug-related adverse event was reported -- subcutaneous induration at the injection site which resolved within two weeks. In comparison, adverse events in these patients observed during a prior regimen containing Revlimid® included nausea, vomiting, deep vein thrombosis (DVT), upper respiratory tract infections (URTI), anemia, and fatigue. None of the more common side effects of lenalidomide (Revlimid®), which include diarrhea, fatigue, anemia, constipation, neutropenia, leukopenia, peripheral edema, insomnia, muscle cramp/spasms, abdominal pain, back pain, nausea, asthenia, pyrexia, bronchitis, nasopharyngitis, gastroenteritis, cough, rash, dyspnea, dizziness, decreased appetite, thrombocytopenia, and tremor, have been observed with STAR-LLD. Up to 30% of patients discontinue use of Revlimid® and roughly 70% dose reduce as a result of these adverse effects. These data suggest that STAR-LLD may prove to be superior in tolerability to oral Revlimid, expanding the number of patients that get the full Revlimid® benefit and improving quality of life.

Key Points: 
  • Patient acceptance of self-administration using the ambulatory pump for lenalidomide delivery has been confirmed in this study.
  • Remarkably, there were no hematologic toxicities greater than Grade 1 observed to date.
  • Only a single drug-related adverse event was reported -- subcutaneous induration at the injection site which resolved within two weeks.
  • Up to 30% of patients discontinue use of Revlimid® and roughly 70% dose reduce as a result of these adverse effects.

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Retrieved on: 
Monday, December 4, 2023

MELBOURNE, Australia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that the US Naval Medical Research Command (NMRC) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.

Key Points: 
  • The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.
  • The clinical study is being led by Principal Investigator Dr Kawsar Talaat, MD at the Johns Hopkins University (JHU) Center for Immunization Research (CIR) Inpatient Unit, located at the JHU Bayview Medical Campus, Baltimore, Maryland.
  • The dosing, challenge and the in-patient stage of the study is anticipated to be completed by the third week of December 2023.
  • The estimated study completion date (last participant, last visit) is June 2024 with headline results from the clinical trial expected to be reported in 2H 2024.